207 related articles for article (PubMed ID: 20620233)
1. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.
Katz G; Khoury A; Kurtzwald E; Hochhauser E; Porat E; Shainberg A; Seidman JG; Seidman CE; Lorber A; Eldar M; Arad M
Heart Rhythm; 2010 Nov; 7(11):1676-82. PubMed ID: 20620233
[TBL] [Abstract][Full Text] [Related]
2. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
[TBL] [Abstract][Full Text] [Related]
3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
4. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
6. The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
Katz G; Shainberg A; Hochhauser E; Kurtzwald-Josefson E; Issac A; El-Ani D; Aravot D; Afek A; Seidman JG; Seidman CE; Eldar M; Arad M
Biochem Pharmacol; 2013 Dec; 86(11):1576-83. PubMed ID: 24070655
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
8. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
[TBL] [Abstract][Full Text] [Related]
9. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
10. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
[TBL] [Abstract][Full Text] [Related]
12. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Rosso R; Kalman JM; Rogowski O; Diamant S; Birger A; Biner S; Belhassen B; Viskin S
Heart Rhythm; 2007 Sep; 4(9):1149-54. PubMed ID: 17765612
[TBL] [Abstract][Full Text] [Related]
13. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.
Kurtzwald-Josefson E; Hochhauser E; Katz G; Porat E; Seidman JG; Seidman CE; Chepurko Y; Shainberg A; Eldar M; Arad M
J Appl Physiol (1985); 2012 Dec; 113(11):1677-83. PubMed ID: 23042908
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Galimberti ES; Knollmann BC
J Mol Cell Cardiol; 2011 Nov; 51(5):760-8. PubMed ID: 21798265
[TBL] [Abstract][Full Text] [Related]
15. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
16. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
Faggioni M; Hwang HS; van der Werf C; Nederend I; Kannankeril PJ; Wilde AA; Knollmann BC
Circ Res; 2013 Feb; 112(4):689-97. PubMed ID: 23295832
[TBL] [Abstract][Full Text] [Related]
17. Electropharmacology of nonsustained ventricular tachycardia: effects of class I antiarrhythmic agents, verapamil and propranolol.
Buxton AE; Waxman HL; Marchlinski FE; Josephson ME
Am J Cardiol; 1984 Mar; 53(6):738-44. PubMed ID: 6702622
[TBL] [Abstract][Full Text] [Related]
18. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
[TBL] [Abstract][Full Text] [Related]
19. Left Cardiac Sympathetic Denervation in Patients with CASQ2-Associated Catecholaminergic Polymorphic Ventricular Tachycardia.
Marai I; Boulos M; Khoury A
Isr Med Assoc J; 2015 Sep; 17(9):538-40. PubMed ID: 26625541
[TBL] [Abstract][Full Text] [Related]
20. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.
Hong RA; Rivera KK; Jittirat A; Choi JJ
Pacing Clin Electrophysiol; 2012 Jul; 35(7):794-7. PubMed ID: 22553997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
